Financials data is unavailable for this security.
View more
Year on year PCI Biotech Holding ASA had revenues fall -37.05% from 4.75m to 2.99m, though the company grew net income from a loss of 55.10m to a smaller loss of 20.32m.
Gross margin | -- |
---|---|
Net profit margin | -266.74% |
Operating margin | -296.63% |
Return on assets | -35.59% |
---|---|
Return on equity | -40.61% |
Return on investment | -40.42% |
More ▼
Cash flow in NOKView more
In 2023, cash reserves at PCI Biotech Holding ASA fell by 15.41m. However, Cash Flow from Investing was flat, indicating that little new money was committed to growth. In addition the company used 14.97m for operations while cash used for financing totalled 442.00k.
Cash flow per share | -0.4197 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.8548 |
---|---|
Tangible book value per share | 0.8548 |
More ▼
Balance sheet in NOKView more
Current ratio | 6.86 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.0149 |
---|---|
Total debt/total capital | 0.0147 |
More ▼